Published in Future Oncol on February 01, 2006
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell (2009) 1.26
Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem (2009) 1.17
Innate immunity to adenovirus. Hum Gene Ther (2014) 1.15
Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther (2009) 1.03
Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther (2009) 1.02
Adenovirus receptors and their implications in gene delivery. Virus Res (2009) 0.98
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther (2009) 0.97
Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer (2010) 0.92
Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One (2012) 0.92
CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J Clin Invest (2009) 0.92
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology (2013) 0.88
Gene therapy of benign gynecological diseases. Adv Drug Deliv Rev (2009) 0.87
Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. Genet Vaccines Ther (2008) 0.86
The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses. J Surg Res (2010) 0.84
Molecular characterization of apoptosis induced by CARF silencing in human cancer cells. Cell Death Differ (2010) 0.83
Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. J Cancer Res Clin Oncol (2012) 0.81
Improving adenovirus based gene transfer: strategies to accomplish immune evasion. Viruses (2010) 0.80
Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans. PLoS One (2012) 0.80
Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy. Virol J (2007) 0.79
Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. BMC Cancer (2009) 0.78
PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts. Cancer Gene Ther (2008) 0.78
Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential. J Virol (2012) 0.77
Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells. Am J Obstet Gynecol (2008) 0.77
A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents. PLoS One (2015) 0.77
Selective killing of Smad4-negative tumor cells via a designed repressor strategy. Mol Pharmacol (2008) 0.75
Characterization of an Oncolytic Adenovirus Vector Constructed to Target the cMet Receptor. Oncolytic Virother (2016) 0.75
Fertile ground: human endometrial programming and lessons in health and disease. Nat Rev Endocrinol (2016) 0.75
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A (2001) 3.46
Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res (2000) 3.37
An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol (1998) 3.32
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol (1996) 2.69
Dosimetric and technical considerations for interstitial adenoviral gene therapy as applied to prostate cancer. Int J Radiat Oncol Biol Phys (2003) 2.67
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med (2000) 2.24
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res (2003) 2.23
Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol (2000) 2.14
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res (2002) 2.06
Coordinately up-regulated genes in ovarian cancer. Cancer Res (2001) 1.93
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther (2001) 1.92
Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev (1999) 1.90
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol (1998) 1.88
Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther (2003) 1.85
The role of chemoattraction in cancer metastases. Bioessays (2001) 1.81
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol (2001) 1.66
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res (1997) 1.60
Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res (1998) 1.59
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55
Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res (1999) 1.54
Targeting adenovirus. Gene Ther (2000) 1.49
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (1999) 1.47
The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res (2001) 1.45
Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther (1995) 1.42
The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther (1998) 1.36
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther (2001) 1.36
Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol (2001) 1.34
Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther (2003) 1.33
Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer (1994) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 1.28
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol (2003) 1.21
Modified adenoviruses for cancer gene therapy. Int J Cancer (2004) 1.18
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16
Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol (2003) 1.13
Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene (2000) 1.12
Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res (2001) 1.11
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther (2001) 1.10
Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther (2005) 1.10
Heparan sulfate proteoglycans in the nervous system: their diverse roles in neurogenesis, axon guidance, and synaptogenesis. Semin Cell Dev Biol (2001) 1.04
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol (2002) 1.03
Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol (2003) 1.01
A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther (1998) 0.98
Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther (2000) 0.97
Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther (2003) 0.96
Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol (2002) 0.96
Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc Med (2002) 0.94
A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res (2001) 0.92
Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol (2000) 0.91
Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res (2002) 0.89
Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer (2004) 0.88
Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther (2004) 0.87
Double genetic modification of adenovirus fiber with RGD polylysine motifs significantly enhances gene transfer to isolated human pancreatic islets. Transplantation (2003) 0.86
Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J Virol (2001) 0.83
Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Oncol Rep (2002) 0.83
Adenoviruses in oncology: a viable option? BioDrugs (2002) 0.83
Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung. Am J Respir Crit Care Med (1997) 0.82
From molecular changes to customised therapy. Eur J Cancer (2002) 0.79
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther (2004) 1.90
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Current issues and future directions of oncolytic adenoviruses. Mol Ther (2009) 1.80
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 1.66
Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. Nanomedicine (2005) 1.66
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther (2003) 1.63
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett (2006) 1.61
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol (2008) 1.52
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene (2005) 1.43
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35
Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
Search for neutrinoless double-beta decay in 136Xe with EXO-200. Phys Rev Lett (2012) 1.33
Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol (2002) 1.33
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A (2011) 1.31
Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res (2007) 1.31
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 1.28
Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology (2004) 1.27
Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther (2009) 1.25
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23
Structure and uncoating of immature adenovirus. J Mol Biol (2009) 1.23
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg (2006) 1.21
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer (2006) 1.19
Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol (2005) 1.19
Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging (2004) 1.18
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther (2008) 1.18
The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res (2002) 1.17
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15
Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther (2009) 1.14
Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res (2002) 1.14
Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol (2008) 1.14
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res (2002) 1.13
Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging (2006) 1.13
Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol (2007) 1.13
Three-dimensional structure of canine adenovirus serotype 2 capsid. J Virol (2008) 1.13
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (2006) 1.12
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Mol Cancer Ther (2008) 1.11
Scavenger receptor A: a new route for adenovirus 5. Mol Pharm (2009) 1.10
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol (2013) 1.10
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther (2008) 1.10
Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst (2006) 1.10
A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression. J Biol Chem (2006) 1.10
Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther (2004) 1.10
Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res (2006) 1.09
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther (2009) 1.08
Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 1.08
Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res (2007) 1.07
HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One (2010) 1.07
Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. J Mol Biol (2008) 1.06
Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology (2002) 1.06
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy (2008) 1.06
Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol (2009) 1.06
Genetic targeting strategies for adenovirus. Mol Pharm (2005) 1.05
Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol (2002) 1.04
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04
A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res (2012) 1.04
OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biol Ther (2010) 1.03
Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology (2005) 1.03
Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J (2008) 1.03
Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol (2003) 1.02
An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology (2004) 1.02
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther (2010) 1.02
Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med (2011) 1.01
YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem (2002) 1.01
Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res (2003) 1.01
Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy? Expert Opin Biol Ther (2007) 1.00
Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res (2007) 1.00
The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther (2002) 1.00
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther (2007) 0.99
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res (2003) 0.99